Anecdotal evidence has suggested that lymphokine-activated killer cells and IL-2 might reduce the formation of pleural effusions [137], and an early trial with IL-2 suggested survival benefit [138], with a subsequent phase II trial reporting tumour responses in 22% of patients with malignant mesothelioma [139]. Here, IL2 is linked to neoplasm.